NASDAQ:PTGX

Protagonist Therapeutics (PTGX) News Headlines

$11.46

-0.25 (-2.13%)

(As of 08/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $11.02
▼
$11.83
50-Day Range: $7.06
▼
$11.71
52-Week Range: $6.91
▼
$50.54

Volume: 831,004 shs
Average Volume: 1.01 million shs
Market Capitalization: $557.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.63

Get Protagonist Therapeutics News Delivered to You Automatically

PTGX Media Mentions By Week

PTGX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PTGX
News Sentiment
▼
1.50

0.34
▲
Average
Medical
News Sentiment

PTGX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PTGX Articles
This Week
▼
2

1
▲
PTGX Articles
Average Week

Source

Source	Headline
	Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from Analysts marketbeat.com - August 6 at 1:47 AM
	Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $50.63 Consensus PT from Analysts americanbankingnews.com - July 15 at 2:32 AM
	MGNI, NRIX and PTGX are among after hour and movers seekingalpha.com - June 4 at 5:02 AM
	Protagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022 seekingalpha.com - June 2 at 11:53 PM
	Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference finance.yahoo.com - June 1 at 4:49 PM
	A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants? finance.yahoo.com - May 26 at 5:20 PM
	Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022 finance.yahoo.com - May 26 at 5:20 PM
	PTGX, MNKD and AVGO are among after hour movers seekingalpha.com - May 20 at 11:54 PM
	7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years finance.yahoo.com - May 19 at 2:00 AM
	Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28% finance.yahoo.com - May 11 at 10:56 AM
	Shareholders in Protagonist Therapeutics (NASDAQ:PTGX) are in the red if they invested a year ago nz.finance.yahoo.com - May 4 at 1:49 PM

	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Protagonist Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – PTGX apnews.com - April 26 at 6:22 PM
	Protagonist Therapeutics shares slid after sharing Phase 2 data for its experimental ulcerative colitis treatment finance.yahoo.com - April 26 at 1:09 PM
	Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis apnews.com - April 25 at 5:06 PM
	Ongoing Investigation Notice: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm apnews.com - April 25 at 12:04 PM
	INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm apnews.com - April 21 at 11:58 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX apnews.com - April 20 at 2:02 AM
	Hot Stocks: CXW hits high on upgrade; CMBM plunges; VALN, PTGX move on regulatory decisions seekingalpha.com - April 14 at 11:03 PM
	Why this East Bay biotech lost nearly 22% of its value finance.yahoo.com - April 14 at 11:03 PM
	The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More msn.com - April 14 at 1:03 PM
	Protagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertide seekingalpha.com - April 14 at 1:03 PM
	Protagonist's stock falls 27% after updating investors about experimental blood disorder drug finance.yahoo.com - April 14 at 1:03 PM
	Protagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern finance.yahoo.com - April 14 at 1:03 PM
	FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer uk.investing.com - April 14 at 8:02 AM
	Asif Ali is the new finance chief at Protagonist Therapeutics seekingalpha.com - March 28 at 9:58 AM
	Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer finance.yahoo.com - March 28 at 9:58 AM
	BiondVax, Alpha Tau top healthcare gainers; Sonendo, Creative Medical among losers seekingalpha.com - March 25 at 9:33 PM
	Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis finance.yahoo.com - March 24 at 5:17 AM
	Protagonist Gets $25 Mln Milestone Payment From Janssen nasdaq.com - March 16 at 11:21 AM
	Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update finance.yahoo.com - February 28 at 5:10 PM
	3 Desirable Drug Stocks With Very Promising Pipelines finance.yahoo.com - February 24 at 7:57 AM
	Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock? finance.yahoo.com - February 16 at 7:39 AM

	Notable Tuesday Option Activity: PTGX, TTCF, PANW nasdaq.com - February 15 at 4:37 PM
	BTIG Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $55 benzinga.com - February 11 at 6:26 PM
	Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference finance.yahoo.com - February 10 at 3:59 PM
	First Week of PTGX February 18th Options Trading nasdaq.com - February 7 at 6:55 PM
	We're Hopeful That Protagonist Therapeutics (NASDAQ:PTGX) Will Use Its Cash Wisely finance.yahoo.com - February 7 at 6:55 PM
	We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth nasdaq.com - January 4 at 3:31 PM
	/C O R R E C T I O N -- Protagonist Therapeutics, Inc./ finance.yahoo.com - January 4 at 3:31 PM
	Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting finance.yahoo.com - December 12 at 10:00 AM
	The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering markets.businessinsider.com - December 3 at 7:57 AM
	Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit finance.yahoo.com - December 3 at 7:57 AM
	What 9 Analyst Ratings Have To Say About Protagonist Therapeutics benzinga.com - November 15 at 5:50 PM
	Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis finance.yahoo.com - November 15 at 7:49 AM
	Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences finance.yahoo.com - November 11 at 8:27 AM
	Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting finance.yahoo.com - November 4 at 11:21 AM
	Hedge Funds Are Crazy About Protagonist Therapeutics, Inc. (PTGX) finance.yahoo.com - October 18 at 6:37 AM
	J.P. Morgan Says There’s Room for Over 40% Upside in These 2 Stocks finance.yahoo.com - October 13 at 10:20 PM
	Analyst Ratings For Protagonist Therapeutics markets.businessinsider.com - October 12 at 3:23 PM
	Where Protagonist Therapeutics Stands With Analysts markets.businessinsider.com - October 11 at 1:37 PM
	Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug finance.yahoo.com - October 11 at 1:37 PM

Get Protagonist Therapeutics News Delivered to You Automatically

This page (NASDAQ:PTGX) was last updated on 8/7/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms